With the introduction of new non-factor treatment options for people with hemophilia (PWH), the landscape of hemophilia treatment has become more complex, which has made the decision-making process for both patients and physicians more complex as well. This reality makes a shared decision-making tool to facilitate the discussion between PWH and healthcare professionals on treatment options essential. The aim of the WFH Shared Decision Making Tool for Hemophilia Treatment is to facilitate the patient-healthcare professional discussion on personal preferences and goals, provide education on the attributes of all therapies, and ultimately, allow PWH to make a truly informed treatment decision.
The shared decision-making model is “a stepwise process that relies on reciprocal information sharing between the practitioner and patient, resulting in health care decisions stemming from the informed preferences of both parties.”
— Valentino LA, et al., The Journal of Haemophilia Practice, 2021
The WFH has partnered with COR2ED, an independent medical education organization, to develop the tool, allowing us to offer a world-class, online, evidence-based, shared decision-making resource. Development is currently underway, and we are on track to launch the WFH Shared Decision Making Tool for Hemophilia Treatment to the community in 2023.
The tool will be offered free of charge to the global hemophilia community and will be available to all WFH national member organizations (NMOs) and all hemophilia treatment centres (HTCs). It will be available on the WFH website in English, with plans to offer it in other languages in the future.
The WFH Hemophilia Treatment Shared Decision Making Tool is supported by funding from Spark Therapeutics and BioMarin Pharmaceutical Inc.